

Country:

1.

Uganda

Support for Vaccine: Rotavirus

This Decision Letter sets out the Programme Terms of a Programme

3. Date of Decision Letter: 31 August 2023

Uganda

4. Date of the Partnership Framework Agreement: 28 June 2013

5. Programme title: New Vaccine Support (NVS), Rotavirus, Routine

6. Vaccine type: Rotavirus

7. Requested product presentation and formulation of vaccine:

RV5, 2 doses/vial, liquid

Rrix, 1 dose/plastic tube, liquid

8. Programme duration: 2018-2027

9. Programme Budget (indicative):2

(subject to the terms of the Partnership Framework Agreement, if applicable)

	2018-2022	2023	2024	2025	2026	2027	Total ²
Programme Budget(US\$)	27,539,820	13,194,072	4,818,582	-	-	-	45,552,474

10. Vaccine introduction grant:

Approval				
Year Grant number Amount (US\$)				
2018	UGA-RV-R-VIG-UNIC	1,506,500		

11. Product switch grant:

Approval
7. pp. 0. 0.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

³This is the amount that Gavi has approved.



Year	Grant number	Amount (US\$)
2023	UGA-RV-R-PSG	552,323

12. Indicative annual amounts:3

(subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2018-2022	2023	2024
Number of vaccine doses	-	6,832,800	5,538,600
Number of AD syringes	-	-	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	-	-
Annual Amounts (US\$)	27,539,820	13,194,072	4,818,582

13. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

14. Self-procurement:

Not applicable

15. Co-financing obligations:

According to the co-financing policy, the within the group:	falls	Initial self-financing			
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2023	2024	2025	2026	2027
Number of vaccine doses	348,000	999,700	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	884,616	799,760	-	-	-
Total co-financing payments (US\$) (including freight)	997,577	869,739	-	-	-

16. Operational support for campaigns:



Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
 vaccine stock levels including buffer stock, by end of March; 	31 March
 number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	15 May
 Countries shall report the actual switch date in the first renewal request following the actual implementation. 	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

1	8.	Financial	clarifications:
---	----	-----------	-----------------

Not applicable

Other conditions: 19.

Not applicable



Colette Selman

Director Core Countries, Country Support

31/8/2023